-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 Jx+3upJTA+6iQgxGfbx8qMpWuOQhC03tLhDuaC9Lt+T/XxxbXjfCgznSr+OZiu9l
 kiFILkvnCxZAYNEaFhq5Og==

<SEC-DOCUMENT>0000890163-07-000213.txt : 20070402
<SEC-HEADER>0000890163-07-000213.hdr.sgml : 20070402
<ACCEPTANCE-DATETIME>20070402101907
ACCESSION NUMBER:		0000890163-07-000213
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20070330
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20070402
DATE AS OF CHANGE:		20070402

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PIPEX PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0000894158
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				133808303
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12584
		FILM NUMBER:		07736126

	BUSINESS ADDRESS:	
		STREET 1:		3985 RESEARCH PARK DRIVE
		CITY:			ANN ARBOR
		STATE:			MI
		ZIP:			48108
		BUSINESS PHONE:		734-332-7800

	MAIL ADDRESS:	
		STREET 1:		3985 RESEARCH PARK DRIVE
		CITY:			ANN ARBOR
		STATE:			MI
		ZIP:			48108

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SHEFFIELD PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19970730

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SHEFFIELD MEDICAL TECHNOLOGIES INC
		DATE OF NAME CHANGE:	19940606
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>s11-7247_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
<TITLE> </TITLE>
</HEAD>
<BODY bgcolor="#ffffff">




<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><b><font SIZE=2>UNITED STATES</font></b></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><b><font SIZE=2>SECURITIES AND EXCHANGE COMMISSION</font></b></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><b><font SIZE=2>WASHINGTON, D.C. 20549</font></b></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><b><font SIZE=3>FORM 8-K</font></b></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><b><font SIZE=2>CURRENT REPORT</font></b></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><b><font size=2>Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</font></b></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><font size=2>Date of Report (date of earliest event reported): April 2, 2007</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><b><font size=5>Pipex Pharmaceuticals, Inc.</font></b></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><font size=2>(Exact name of registrant as specified in charter)</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><b><font size=2>Delaware</font></b></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><font size=2>(State or other jurisdiction of incorporation)</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><font size=2>&nbsp;</font></p>


<table border="0" cellspacing=0 cellpadding=0 width="98%" style='border-collapse:collapse'>
    <tr >
        <td width="48%" valign=top >
            <p style='margin-left:0pt;text-indent:0pt;text-align:center;margin-top:0pt;margin-bottom:0pt'><font size=2>01-12584 &nbsp;</font></p>
<p style='margin-left:0pt;text-indent:0pt;text-align:center;margin-top:0pt;margin-bottom:0pt'><font size=2>(Commission File Number)</font></p> </td>
        <td width="51%" valign=top >
            <p style='margin-left:0pt;text-indent:0pt;text-align:center;margin-top:0pt;margin-bottom:0pt'><font size=2>13-3808303 &nbsp;</font></p>
<p style='margin-left:0pt;text-indent:0pt;text-align:center;margin-top:0pt;margin-bottom:0pt'><font size=2>(IRS Employer Identification No.)</font></p> </td> </tr></table>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><font size=2>&nbsp;</font></p>


<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" WIDTH="99%" STYLE="border-collapse:collapse">
    <tr >
        <TD WIDTH="37.5%" VALIGN="TOP" STYLE="padding:0in 5.4pt 0in 5.4pt">
            <p style='margin-left:0pt;text-indent:0pt;text-align:center;margin-top:0pt;margin-bottom:0pt'><b>&nbsp;</b></p> </td>
        <TD WIDTH="25%" VALIGN="TOP" STYLE="padding:0in 5.4pt 0in 5.4pt">
            <p style='margin-left:0pt;text-indent:0pt;text-align:center;margin-top:0pt;margin-bottom:0pt'><b><font size=2>3985 Research Park Drive</font></b></p> </td>
        <TD WIDTH="37.5%" VALIGN="TOP" STYLE="padding:0in 5.4pt 0in 5.4pt">
            <p style='margin-left:0pt;text-indent:0pt;text-align:center;margin-top:0pt;margin-bottom:0pt'><b>&nbsp;</b></p> </td> </tr>
    <tr >
        <TD VALIGN="TOP" STYLE="padding:0in 5.4pt 0in 5.4pt">
            <p style='margin-left:0in;text-indent:0pt;text-align:center;margin-top:1.0pt;margin-bottom:0in'><b>&nbsp;</b></p> </td>
        <TD VALIGN="TOP" STYLE="border-bottom:solid black 1.0pt; padding:0in 5.4pt 0in 5.4pt">
            <p style='margin-left:0pt;text-indent:0pt;text-align:center;margin-top:0pt;margin-bottom:0pt'><b><font size=2>Ann Arbor, MI 48108</font></b></p> </td>
        <TD VALIGN="TOP" STYLE="padding:0in 5.4pt 0in 5.4pt">
            <p style='margin-left:0in;text-indent:0pt;text-align:center;margin-top:1.0pt;margin-bottom:0in'><b>&nbsp;</b></p> </td> </tr>
    <tr style='height:12.6pt'>
        <TD VALIGN="TOP" STYLE="padding:0in 5.4pt 0in 5.4pt; height:12.6pt">
            <p style='margin-left:0pt;text-indent:0pt;text-align:center;margin-top:8.5pt;margin-bottom:0pt'><font size=1>&nbsp;</font></p> </td>
        <TD VALIGN="TOP" STYLE="padding:0in 5.4pt 0in 5.4pt;height:12.6pt">
            <p style='margin-left:0pt;text-indent:0pt;text-align:center;margin-top:0pt;margin-bottom:0pt'><font size=2>(Address of principal executive offices and zip code)</font></p> </td>
        <TD VALIGN="TOP" STYLE="padding:0in 5.4pt 0in 5.4pt; height:12.6pt">
            <p style='margin-left:0pt;text-indent:0pt;text-align:center;margin-top:8.5pt;margin-bottom:0pt'><font size=1>&nbsp;</font></p> </td> </tr>
    <tr >
        <TD VALIGN="TOP" STYLE="padding:0in 5.4pt 0in 5.4pt">
            <p style='margin-left:0pt;text-indent:0pt;text-align:center;margin-top:0pt;margin-bottom:0pt'><font size=1>&nbsp;</font></p> </td>
        <TD VALIGN="TOP" STYLE="padding:0in 5.4pt 0in 5.4pt">
            <p style='margin-left:0pt;text-indent:0pt;text-align:center;margin-top:0pt;margin-bottom:0pt'><font size=1>&nbsp;</font></p> </td>
        <TD VALIGN="TOP" STYLE="padding:0in 5.4pt 0in 5.4pt">
            <p style='margin-left:0pt;text-indent:0pt;text-align:center;margin-top:0pt;margin-bottom:0pt'><font size=1>&nbsp;</font></p> </td> </tr>
    <tr >
        <TD VALIGN="TOP" STYLE="padding:0in 5.4pt 0in 5.4pt">
            <p style='margin-left:0pt;text-indent:0pt;text-align:center;margin-top:1.0pt;margin-bottom:0pt'><font size=1>&nbsp;</font></p> </td>
        <TD VALIGN="TOP" STYLE="border-bottom:solid black 1.0pt; padding:0in 5.4pt 0in 5.4pt">
            <p style='margin-left:0pt;text-indent:0pt;text-align:center;margin-top:0pt;margin-bottom:0pt'><font size=2>(734) 332-7800</font></p> </td>
        <TD VALIGN="TOP" STYLE="padding:0in 5.4pt 0in 5.4pt">
            <p style='margin-left:0pt;text-indent:0pt;text-align:center;margin-top:1.0pt;margin-bottom:0pt'><font size=1>&nbsp;</font></p> </td> </tr>
    <tr style='height:19.1pt'>
        <TD VALIGN="TOP" STYLE="padding:0in 5.4pt 0in 5.4pt; height:19.1pt">
            <p style='margin-left:0in;text-indent:0pt;text-align:center;margin-top:8.5pt;margin-bottom:0in;line-height:8.1%'><font size=1>&nbsp;</font></p> </td>
        <TD VALIGN="TOP" STYLE="padding:0in 5.4pt 0in 5.4pt;height:19.1pt">
            <p style='margin-left:0pt;text-indent:0pt;text-align:center;margin-top:0pt;margin-bottom:0pt'><font size=2>(Registrant&#146;s telephone number including area code)</font></p> </td>
        <TD VALIGN="TOP" STYLE="padding:0in 5.4pt 0in 5.4pt; height:19.1pt">
            <p style='margin-left:0in;text-indent:0pt;text-align:center;margin-top:8.5pt;margin-bottom:0in;line-height:8.1%'><font size=1>&nbsp;</font></p> </td> </tr>
    <tr >
        <TD VALIGN="TOP" STYLE="padding:0in 5.4pt 0in 5.4pt">
            <p style='margin-left:0pt;text-indent:0pt;text-align:center;margin-top:0pt;margin-bottom:0pt'><font size=1>&nbsp;</font></p> </td>
        <TD VALIGN="TOP" STYLE="padding:0in 5.4pt 0in 5.4pt">
            <p style='margin-left:0pt;text-indent:0pt;text-align:center;margin-top:0pt;margin-bottom:0pt'><font size=1>&nbsp;</font></p> </td>
        <TD VALIGN="TOP" STYLE="padding:0in 5.4pt 0in 5.4pt">
            <p style='margin-left:0pt;text-indent:0pt;text-align:center;margin-top:0pt;margin-bottom:0pt'><font size=1>&nbsp;</font></p> </td> </tr>
    <tr >
        <TD VALIGN="TOP" STYLE="padding:0in 5.4pt 0in 5.4pt">
            <p style='margin-left:0in;text-indent:0pt;text-align:center;margin-top:1.0pt;margin-bottom:0in'><font size=1>&nbsp;</font></p> </td>
        <TD VALIGN="TOP" STYLE="border-bottom:solid black 1.0pt; padding:0in 5.4pt 0in 5.4pt">
            <p style='margin-left:0pt;text-indent:0pt;text-align:center;margin-top:0pt;margin-bottom:0pt'><font SIZE=2>N/A</font></p> </td>
        <TD VALIGN="TOP" STYLE="padding:0in 5.4pt 0in 5.4pt">
            <p style='margin-left:0in;text-indent:0pt;text-align:center;margin-top:1.0pt;margin-bottom:0in'><font size=1>&nbsp;</font></p> </td> </tr>
    <tr >
        <TD VALIGN="TOP" STYLE="padding:0in 5.4pt 0in 5.4pt">
            <p style='margin-left:0pt;text-indent:0pt;text-align:center;margin-top:8.5pt;margin-bottom:0pt'><font size=1>&nbsp;</font></p> </td>
        <TD VALIGN="TOP" STYLE="padding:0in 5.4pt 0in 5.4pt">
            <p style='margin-left:0pt;text-indent:0pt;text-align:center;margin-top:0pt;margin-bottom:0pt'><font size=2>(Former Name and Former Address)</font></p> </td>
        <TD VALIGN="TOP" STYLE="padding:0in 5.4pt 0in 5.4pt">
            <p style='margin-left:0pt;text-indent:0pt;text-align:center;margin-top:8.5pt;margin-bottom:0pt'><font size=1>&nbsp;</font></p> </td> </tr></table>

<p style=' margin-bottom:0pt; margin-top:0pt; text-indent:0.5in;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt; text-indent:0.5in;text-align:left;'><font size=2>Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>


<table border="0" cellspacing=0 cellpadding=0 width="109%" style='border-collapse:collapse'>
    <tr >
        <td width="8%" valign=top >
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=2>&nbsp;</font></p> </td>
        <td width="8%" valign=top >
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font face=Wingdings>o</font></p> </td>
        <td width="83%" valign=top >
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=2>Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></p> </td> </tr>
    <tr >
        <td width="8%" valign=top >
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=1>&nbsp;</font></p> </td>
        <td width="8%" valign=top >
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=1>&nbsp;</font></p> </td>
        <td width="83%" valign=top >
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=1>&nbsp;</font></p> </td> </tr>
    <tr >
        <td width="8%" valign=top >
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=2>&nbsp;</font></p> </td>
        <td width="8%" valign=top >
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font face=Wingdings>o</font></p> </td>
        <td width="83%" valign=top >
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=2>Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12)</font></p> </td> </tr>
    <tr >
        <td width="8%" valign=top >
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=1>&nbsp;</font></p> </td>
        <td width="8%" valign=top >
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=1>&nbsp;</font></p> </td>
        <td width="83%" valign=top >
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=1>&nbsp;</font></p> </td> </tr>
    <tr >
        <td width="8%" valign=top >
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=2>&nbsp;</font></p> </td>
        <td width="8%" valign=top >
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font face=Wingdings>o</font></p> </td>
        <td width="83%" valign=top >
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=2>Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))&nbsp;</font></p> </td> </tr>
    <tr >
        <td width="8%" valign=top >
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=1>&nbsp;</font></p> </td>
        <td width="8%" valign=top >
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=1>&nbsp;</font></p> </td>
        <td width="83%" valign=top >
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=1>&nbsp;</font></p> </td> </tr>
    <tr >
        <td width="8%" valign=top >
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=2>&nbsp;</font></p> </td>
        <td width="8%" valign=top >
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font face=Wingdings>o</font></p> </td>
        <td width="83%" valign=top >
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=2>Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></p> </td> </tr></table>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:8.5pt;text-align:center;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>
<br>
<HR noshade align="center" width="100%" size="2">
<p style='page-break-before:always'></p>
<pAGE>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><b><font size=2>Item 2.02 &#150; Results of Operations and Financial Condition.</font></b></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt; text-indent:0.5in;text-align:left;'><font size=2>On April 2, 2007, Pipex Pharmaceuticals, Inc., a Delaware corporation (the &#147;Registrant"), issued the attached press release that included financial information for its fourth quarter and fiscal year ended December 31, 2006. A copy of the press release is attached as Exhibit 99.1 to this Report on Form 8-K. The information contained in the press release is being furnished to the Commission and shall not be deemed incorporated by reference into any of the Registrant&#146;s registration statements or other filings with the Commission.  </font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><font size=2>&nbsp;</font></p>


<table border="0" cellspacing=0 cellpadding=0 width="98%" style='border-collapse:collapse'>
    <tr >
        <td width="15%" valign=top style='padding:0in 5.4pt 0in 5.4pt'>
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><b><font size=2>Item 9.01</font></b><font size=2> &nbsp;</font></p> </td>
        <td width="84%" valign=top style='padding:0in 5.4pt 0in 5.4pt'>
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><b><font size=2>Financial Statements and Exhibits.</font></b></p> </td> </tr>
    <tr >
        <td width="15%" valign=top style='padding:0in 5.4pt 0in 5.4pt'>
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=1>&nbsp;</font></p> </td>
        <td width="84%" valign=top style='padding:0in 5.4pt 0in 5.4pt'>
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=1>&nbsp;</font></p> </td> </tr>
    <tr style='height:14.85pt'>
        <td width="15%" valign=top style='padding:0in 5.4pt 0in 5.4pt; height:14.85pt'>
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)</font></p> </td>
        <td width="84%" valign=top style='padding:0in 5.4pt 0in 5.4pt; height:14.85pt'>
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=2>Exhibits.  </font></p> </td> </tr>
    <tr style='height:14.85pt'>
        <td width="15%" valign=top style='padding:0in 5.4pt 0in 5.4pt; height:14.85pt'>
            <p style='margin-left:0pt;text-indent:0pt;text-align:right;margin-top:0pt;margin-bottom:0pt'><font size=1>&nbsp;</font></p> </td>
        <td width="84%" valign=top style='padding:0in 5.4pt 0in 5.4pt; height:14.85pt'>
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=2>Exhibit 99.1 Press Release issued by Pipex Pharmaceuticals, Inc. dated April 2, 2007.</font></p>
<p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=1>&nbsp;</font></p> </td> </tr></table>

<p style=' margin-bottom:0pt; margin-top:0pt; margin-left:0.5in;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt; margin-left:0.77in;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'>
</p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>
<br>
<HR noshade align="center" width="100%" size="2">
<p style='page-break-before:always'></p>
<pAGE>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><font SIZE=2>SIGNATURES</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></p>
<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>Dated:  April 2, 2007 </font></p>


<table border="0" cellspacing=0 cellpadding=0 width="98%" style='border-collapse:collapse'>
    <tr style='height:26.25pt'>
        <td width="63%" valign=top style='padding:0in 5.4pt 0in 5.4pt; height:26.25pt'>
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=2></font></p> </td>
        <td width="36%" valign=top style='padding:0in 5.4pt 0in 5.4pt; height:26.25pt'>
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><u><font size=2>Pipex Pharmaceuticals, Inc.</font></u></p>
<p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=2>(Registrant)</font></p> </td> </tr>
    <tr >
        <td width="63%" valign=top style='padding:0in 5.4pt 0in 5.4pt'>
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=1>&nbsp;</font></p> </td>
        <td width="36%" valign=top style='padding:0in 5.4pt 0in 5.4pt'>
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=1>&nbsp;</font></p> </td> </tr>
    <tr style='height:42.75pt'>
        <td width="63%" valign=top style='padding:0in 5.4pt 0in 5.4pt; height:42.75pt'>
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=1>&nbsp;</font></p> </td>
        <td width="36%" valign=top style='padding:0in 5.4pt 0in 5.4pt; height:42.75pt'>
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=2>By:&nbsp; </font><u><font size=2>/s/ Steve H. Kanzer&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></u><font size=2>&nbsp;</font></p>
<p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=2>Name: Steve H. Kanzer</font></p>
<p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=2>Title: Chief Executive Officer</font></p> </td> </tr></table>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'>
</p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>
<br>
<HR noshade align="center" width="100%" size="2">
<p style='page-break-before:always'></p>
<pAGE>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><b><font SIZE=2>EXHIBIT INDEX</font></b></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>


<table border="0" cellspacing=0 cellpadding=0 width="106%" style='border-collapse:collapse'>
    <tr >
        <td width="15%" valign=top style='padding:0in 5.4pt 0in 5.4pt'>
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><u><font size=2>Exhibit No</font></u><font size=2>.</font></p> </td>
        <td width="84%" valign=top style='padding:0in 5.4pt 0in 5.4pt'>
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><u><font size=2>Exhibits.</font></u></p> </td> </tr>
    <tr >
        <td width="15%" valign=top style='padding:0in 5.4pt 0in 5.4pt'>
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=1>&nbsp;</font></p> </td>
        <td width="84%" valign=top style='padding:0in 5.4pt 0in 5.4pt'>
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=1>&nbsp;</font></p> </td> </tr>
    <tr style='height:14.85pt'>
        <td width="15%" valign=top style='padding:0in 5.4pt 0in 5.4pt; height:14.85pt'>
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=2>99.1</font></p> </td>
        <td width="84%" valign=top style='padding:0in 5.4pt 0in 5.4pt; height:14.85pt'>
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=2>Press Release issued by Pipex Pharmaceuticals, Inc. dated April 2, 2007</font></p> </td> </tr></table>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt; margin-left:1in; text-indent:0.5in;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'>
</p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>
<br>
<HR noshade align="center" width="100%" size="2">



</BODY>
</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>s11-7247_ex991.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
<TITLE> </TITLE>
</HEAD>
<BODY bgcolor="#ffffff">



<p style=' margin-bottom:0pt; margin-top:0pt;text-align:right;'><font size=2>Exhibit 99.1</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><img src="img1.jpg"><br> </p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:3pt; margin-top:12pt;text-align:center;'><b><font size=5>Pipex Pharmaceuticals Announces Fourth Quarter and Year End 2006 Results</font></b></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><b><font size=2>Webcast/Conference Call Monday, April 2</font><sup><font size=2>nd</font></sup><font size=2> at 8:30 a.m. EST</font></b></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><font size=2>Ann Arbor, Michigan, April 2, 2007 -- Pipex Pharmaceuticals, Inc. (OTC BB: PPXP), a specialty pharmaceutical company developing innovative late-stage drug candidates for the treatment of neurologic and fibrotic diseases, today announced its results for the fourth quarter and year end 2006. </font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><font size=2>Achievements and accomplishments for fourth quarter and year end 2006 included:</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><font size=2>&nbsp;</font></p>


<table border="0" cellspacing=0 cellpadding=0 width="86%" style='margin-left:1.0in;border-collapse:collapse'>
    <tr >
        <td width="10%" valign=top style='padding:0in 5.4pt 0in 5.4pt'>
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=4><b>&#149;</b></font>                                     </p> </td>
        <td width="89%" valign=top style='padding:0in 5.4pt 0in 5.4pt'>
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=2>Completion of private equity financing in fourth quarter 2006 of $13.9 million with leading institutional investors;</font></p> </td> </tr>
    <tr >
        <td width="10%" valign=top style='padding:0in 5.4pt 0in 5.4pt'>
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=4><b>&#149;</b></font>                                     </p> </td>
        <td width="89%" valign=top style='padding:0in 5.4pt 0in 5.4pt'>
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=2>Increased working capital through the conversion of &#126;$3.4 million in bridge loans into common stock;</font></p> </td> </tr>
    <tr >
        <td width="10%" valign=top style='padding:0in 5.4pt 0in 5.4pt'>
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=4><b>&#149;</b></font>                                     </p> </td>
        <td width="89%" valign=top style='padding:0in 5.4pt 0in 5.4pt'>
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=2>Went public in November 2006 via reverse merger with the former Sheffield Pharmaceuticals, Inc., changed corporate name to Pipex Pharmaceuticals, Inc. and initiated trading under new ticker symbol &#147;PPXP&#148;</font></p> </td> </tr>
    <tr >
        <td width="10%" valign=top style='padding:0in 5.4pt 0in 5.4pt'>
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=4><b>&#149;</b></font>                                     </p> </td>
        <td width="89%" valign=top style='padding:0in 5.4pt 0in 5.4pt'>
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=2>Presentation of results of pivotal phase III clinical trial of COPREXA&#153; (oral tetrathiomolybdate) for neurologically presenting Wilson&#146;s disease at NIH Symposium for Wilson&#146;s disease, by Dr. George Brewer, Professor Emeritus, University of Michigan;</font></p> </td> </tr>
    <tr >
        <td width="10%" valign=top style='padding:0in 5.4pt 0in 5.4pt'>
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=4><b>&#149;</b></font>                                     </p> </td>
        <td width="89%" valign=top style='padding:0in 5.4pt 0in 5.4pt'>
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=2>Publication of results of pivotal phase III clinical trial of COPREXA&#153; (oral tetrathiomolybdate) for neurologically presenting Wilson&#146;s disease in </font><i><font size=2>Archives of Neurology</font></i><font size=2>;</font></p> </td> </tr>
    <tr >
        <td width="10%" valign=top style='padding:0in 5.4pt 0in 5.4pt'>
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=4><b>&#149;</b></font>                                     </p> </td>
        <td width="89%" valign=top style='padding:0in 5.4pt 0in 5.4pt'>
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=2>Publication of results of preclinical studies demonstrating COPREXA&#146;s ability to protect against doxorubicin-induced cardiotoxicity in the journal, </font><i><font size=2>Translation Research</font></i><font size=2>;</font></p> </td> </tr>
    <tr >
        <td width="10%" valign=top style='padding:0in 5.4pt 0in 5.4pt'>
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=4><b>&#149;</b></font>                                     </p> </td>
        <td width="89%" valign=top style='padding:0in 5.4pt 0in 5.4pt'>
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=2>Recruited Dr. Charles Bisgaier; former co-founder of Esperion Therapeutics Inc. and co-developer of Lipitor&reg;, to serve as President and board member;</font></p> </td> </tr>
    <tr >
        <td width="10%" valign=top style='padding:0in 5.4pt 0in 5.4pt'>
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=4><b>&#149;</b></font>                                     </p> </td>
        <td width="89%" valign=top style='padding:0in 5.4pt 0in 5.4pt'>
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=2>Received research equipment award from the State of Michigan and SPARK Foundation;</font></p> </td> </tr></table>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'>
</p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>
<br>
<HR noshade align="center" width="100%" size="2">
<p style='page-break-before:always'></p>
<pAGE>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>


<table border="0" cellspacing=0 cellpadding=0 width="86%" style='margin-left:1.0in;border-collapse:collapse'>
    <tr >
        <td width="10%" valign=top style='padding:0in 5.4pt 0in 5.4pt'>
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=4><b>&#149;</b></font>                                     </p> </td>
        <td width="89%" valign=top style='padding:0in 5.4pt 0in 5.4pt'>
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=2>Completion of one year open label phase II clinical trial of COPREXA&#153; for refractory idiopathic pulmonary fibrosis (IPF) with COPREXA&#153; (oral tetrathiomolybdate); and</font></p> </td> </tr>
    <tr >
        <td width="10%" valign=top style='padding:0in 5.4pt 0in 5.4pt'>
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=4><b>&#149;</b></font>                                     </p> </td>
        <td width="89%" valign=top style='padding:0in 5.4pt 0in 5.4pt'>
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=2>Initiation of double-blind placebo controlled phase II clinical trial for of COPREXA&#153; for primary biliary cirrhosis supported by grant of $890,000 from FDA&#146;s Orphan Products Group</font></p> </td> </tr></table>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><font size=2>Financial Results for Fourth Quarter and Year End 2006:</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><font size=2>At December 31, 2006, Pipex had approximately $12.2 million of cash and working capital of approximately $11.5 million, compared to $1.1 million of cash and working capital of ($985,968) at December 31, 2005. The $11.1 million increase in cash is attributable primarily to the net proceeds from our $13.9 million fourth quarter 2006 private equity financing.  Our increase in working capital is attributed to such financing as well as the conversion of approximately $3.4 million of short term loans made prior to the fourth quarter into equity of the company on the same basis as investors in our $13.9 million fourth quarter financing..</font></p>

<p style=' margin-bottom:5pt; margin-top:5pt;text-align:justify;'><font size=2>The net loss applicable to common shareholders for the fourth quarter ended December 31, 2006 was $2,680,557, or $0.09 per share, compared to a net loss applicable to common shareholders of $475,781, or $0.33 per share, for the comparable quarter in 2005, representing an increase in net loss of $2,204,776.  Of this amount, only $1,153,832 represented cash expenses incurred in the fourth quarter while $1,526,725 represented non-cash, non-recurring expenses relating to equity issued in consideration of license fees under our COPREXA&#153; license and an accrued dividend on one of our subsidiary&#146;s preferred stock since retired..</font></p>

<p style=' margin-bottom:5pt; margin-top:5pt;text-align:justify;'><font size=2>The net loss applicable to common shareholders for the year ended December 31, 2006 was $4,860,095, or $0.50 per share, compared to the net loss applicable to common shareholders of $1,546,092, or $1.71 per share, for the year ended December 31, 2005, representing an increase of $3,314,003. The increase in net loss was attributable to an increase in research and development expenses of $1,719,490 that primarily related to Pipex&#146;s COPREXA&#153; NDA directed activities as well as activities associated with development of our other product candidates, TRIMESTA&#153;, CORRECTA&#153;, Anti-CD4 802-2 and EFFIRMA&#153;. The increase in net loss was also due to $1,696,950 in non-cash expenses relating to equity issued in consideration of license fees under our COPREXA&#153; license and an accrued dividend on one of our subsidiary&#146;s preferred stock since retired.</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><font size=2>Steve H. Kanzer, Chairman and Chief Executive Officer, commented on the financial results, &#147;During the fourth quarter 2006 we completed a $13.9 million equity financing with leading institutional investors and became publicly traded for the first time in our six year history.  Today&#146;s filing of our 2006 annual report is our first as a public company.  We are making substantial progress in assembling our New Drug Application (NDA) for COPREXA&#153; (oral tetrathiomolybdate) for the neurologically presenting Wilson&#146;s </font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><font size=2>&nbsp;</font></p>
<br>
<HR noshade align="center" width="100%" size="2">
<p style='page-break-before:always'></p>
<pAGE>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><font size=2>disease and we plan to file our NDA later this year.  We are also very optimistic about the opportunity to build the therapeutic utility of COPREXA&#153; into other disease indications also characterized by high unmet medical needs, such as idiopathic pulmonary fibrosis (IPF), an indication in which COPREXA&#153; has already completed a one-year, open label phase II clinical trial&#148;.</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><font size=2>Today, April 2</font><sup><font size=2>nd</font></sup><font size=2>, at 8:30am EST, Pipex will host an investor conference call during which a brief financial overview of the Company's fourth quarter financial results will be provided.</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><FONT SIZE="2">In order to participate in the webcast/conference call, please call toll free: 800-418-6860 (US); international dial-in: 973-935-8756 before the scheduled start of the call. A visual presentation will be available at: <U>http://www.visualwebcaster.com/event.asp?id=38758</U>. The audio recording and visual presentation will be available for replay at <U>http://www.pipexpharma.com </U>for a period of at least15 days after the call. </FONT> </p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><b><font size=2>About Pipex Pharmaceuticals, Inc. </font></b></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><font size=2>Pipex Pharmaceuticals, Inc. is a specialty pharmaceutical company that is developing proprietary, late-stage drug candidates for the treatment of neurologic and fibrotic diseases.  Pipex&#146;s strategy is to exclusively in-license proprietary, clinical-stage drug candidates and complete the further clinical testing, manufacturing and regulatory requirements sufficient to seek marketing authorizations via the filing of New Drug Applications (NDAs) with the FDA in the U.S. and Marketing Application Authorizations (MAAs) with the European Medicines Evaluation Agency (EMEA).  For further information, please visit, www.pipexpharma.com.  </font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:5pt; margin-top:5pt;text-align:justify;'><font size=2>This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, that reflect Pipex Pharmaceuticals, Inc. and subsidiaries (&#147;we&#148;,&#147;our&#148; or &#147;Company&#148;) current expectations about its future results, performance, prospects and opportunities, including statements regarding the potential uses of COPREXA&#153; for various uses including the treatment of Alzheimer&#146;s disease, inflammatory and fibrotic diseases, as well as its the prospects for regulatory filings in the treatment of neurologic Wilson&#146;s disease.  Where possible, the Company has tried to identify these forward-looking statements by using words such as "anticipates," "believes," "intends," or similar expressions. These statements are subject to a number of risks, uncertainties and other factors that could cause actual events or results in future
periods to differ materially from what is expressed in, or implied by, these statements. We cannot assure you that we will be able to successfully develop or commercialize products based on our technologies, including COPREXA&#153;, TRIMESTA&#153;, SOLOVAX&#153;, EFFIRMA&#153; or Anti-CD4 802-2, particularly in light of the significant uncertainty inherent in developing, manufacturing and conducting preclinical and clinical trials of new pharmaceuticals, and obtaining regulatory approvals, that our technologies will prove to be safe and effective, that our cash expenditures will not exceed projected levels, that we will be able to obtain future financing or funds when needed, that product </font></p>

<p style=' margin-bottom:0pt; margin-top:5pt;text-align:justify;'><font size=2>&nbsp;</font></p>
<br>
<HR noshade align="center" width="100%" size="2">
<p style='page-break-before:always'></p>
<pAGE>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:5pt; margin-top:5pt;text-align:justify;'><font size=2>development and commercialization efforts will not be reduced or discontinued due to difficulties or delays in clinical trials or due to lack of progress or positive results from research and development efforts, that we will be able to successfully obtain any further grants and awards, maintain our existing grants which are subject to performance, that we will be able to patent, register or protect our technology from challenge and products from competition or maintain or expand our license agreements with our current licensors, or that our business strategy will be successful. All forward-looking statements made in this press release are made as of the date hereof, and the Company assumes no obligation to update the forward-looking statements included in this news release whether as a result of new information, future events, or otherwise, other than as required by law. The forward-looking statements are
subject to risks and uncertainties that could cause actual results to differ materially from those set forth or implied by any forward- looking statements, including risks detailed in the Company&#146;s SEC reports, including the Company&#146;s Form 10-KSB. Copies of the filings are available at www.sec.gov.</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>For Further Information Contact:</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>Steve H. Kanzer, CPA, Esq.</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>Chairman and Chief Executive Officer</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>(734) 332-7800</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>Charles Bisgaier, Ph.D.</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>President</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>(734) 332-7800</font> </p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'>&nbsp;</p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>Redington, Inc. (Investor Relations)</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>Thomas Redington</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>203-222-7399</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><FONT SIZE="2"><U>www.redingtoninc.com</U> </FONT></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'>&nbsp;</p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>


<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'>&nbsp;</p>



</BODY>
</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img1.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``H'!P@'!@H("`@+"@H+#A@0#@T-
M#AT5%A$8(Q\E)"(?(B$F*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_
MVP!#`0H+"PX-#AP0$!P[*"(H.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[
M.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SO_P``1"`!G`9(#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#V:BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB
M@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`
M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBDH`6BBB@`HI*6@`I**\VUSQ-K
MEIJ>H10:@Z1PS,J`1IA1V'(II7&E<]*HJ&U8O;1.QRS(I)]\5+2$+1110`44
M4E`"T4E+0`444E`"T444`%%%%`!1110`444E`"T4E+0`4444`%%%%`!1110`
M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!2'I2T4`><>)]7O+7Q
M'>0KK-Q;1H$V1I(`!\HSVK$;Q%J8)QK]R0#P?.'^%>N/:V\CEY((G8]2R`FD
M^Q6A_P"76'_OV*KF\_R_R&G;H>1CQ'JAS_Q/KKZB84G_``D6J8YUZZX])A7K
MOV*T_P"?6'_OV*/L5I_SZP_]^Q1S>?Y?Y%<R['F.G>*]>@=634!>K_SRG`(;
M_@0Y!KT+0]:M]<L!<P@HRG;+$WWHV]#6+XPT"S&ES:E;01P7-OART:A=ZYY!
M]:R?!T[0^)C&O"7=N=XS_$O0_D34WN]26T>A5Y+XB5CJVJOF',<[8#6L39Z=
M25S7K5>0>(V/]NZHH/6=ZJ+M^'YCBKGK-F/]$A_ZYK_*LKQA<2VOANYG@N&M
MY%*8D5MI'SCO6M:?\></_7-?Y5(Z)(I5U#*>H89%):,D\@DUZ]!PFOWK?]MS
M49U_4\`'6[WN?^/@UZ_]DM_^?>+_`+X%`M;<=((_^^!3OYO\/\BE*W0\?.O:
ME_T&KWGI_I#?XT^+Q!J@E79K=X&ST,VX?D<UZ]]F@_YX1_\`?`J&YTRQNXC%
M/:02(>"&C%'-Y_E_D/F78Y+0/&=S]HAM=8VNLK;8[I%VC)Z!QTY]17;CI7E6
MM:3'IVI7NF*&:`*'BR<[5(Z?@?TKT/P]=O?>'K"YD)+O"NXD=2."?TJ+D7U(
M/$7B"+0[9,1^==3$B&$-C=ZDGL!7GVH>)];GE;S]4DB'_/.`B-5]@1R?SJ[X
MGN3+XDU&=_F%LJPH#T`QD_F2:U$MH?"_A:#4X[*WNKZ=DWO/T&_G`/8"J5[V
M7]?>5%KL<>=6OC@'5K_(Y_X^I!_6E_M:^'35+[_P+D_QKHW\=ZI&VU],T\>^
M6IO_``L#4^^G:?\`FU.Z_F_&/^1IK_*<_'JMRY^?5]07Z73_`.-=+X*O))_$
M/EG4+JX3[.Q*S3.PSD<X--3QYJLC;4TZPX]2U;'ASQ+?:IK'V*[M+2(>29-T
M).>"!CGZT7WUO]WZ(SEOJK'43DBWD(/(0_RKR&/4I6MD,NL:BDA&2!<2<'\Z
M]BZT@11T4#\*E.R_K];DGC<FI78(V:I?LOK]JD_QJ:U\0:K:ONMM6N<]2LLA
MD!_!LUZ]M7T'Y5FZUH=EJ]G)'-"GF8)CEVC<C=B#33??\O\`(TYUV.1E^(-X
MVFB..U1+TG#3=8P/[P7KGV/ZUSUQKFIW$Q:?5[MG]$E*`?@N,57AA-Q/#;@[
M7ED6+<!G:2<9_6O7M-TJRTN!8;2WCC4#!(4;F/J3W-"D_3^O,;Y8]+GE"ZK.
M`"^K7Z_]O,G/ZU8MM2E^UVHCU6_D8SQ@JUQ(006%>MX'H*-H]!23=[W_`"_R
M,V[A2T44""BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"D/
M`I:2@#`?QQH".R&[DW(2"!`_4'![4W_A._#W_/W)_P"`\G^%<(WF$ND6-TET
MT8)Z#+XY_.M5_`6NOD^;8`G_`*:/_P#$T^KT_'_@#C9[LZ;_`(3KP[_S^/\`
M^`\G^%)_PG?A_.!<RY_Z]W_PKF?^$`UPX_>6/_?U_P#XF@?#_6\_ZVQ7W$C_
M`/Q-&G;\?^`7RP[ECQ'XNCUFU.G:?%*L,C#S9I!MRHYP!U_&I?`]DUSJLVH@
M$P6\9AC;^\YQNQ]`/UIUC\/I?,!U#4`T?>*!",^VX]OH*[.TL[>QMDMK6)8H
M8QA$4<`4B&ET)J\@\2@G7-4(''GOS7K]<+JO@S5K[4+V>&6S6*YD+`.6W`>^
M!37^7YCB[':VG_'G#_US7^55-6URPT1(GOI'02L539&7R0,]A5VW0QP1HW)5
M0./I7)^/1\VE]?\`6OT_W:7FR'HB[_PGOA__`)^)OQMW_P`*#X]\/CK<R_A`
M_P#A7':=H&H^(#<&TGMD6WDV-YNX$G&>P/:KP^'NL=[NR_-_\*:]/Q_X!HE&
MVK.B_P"$]\/_`//S+_WX?_"H;CXA:*B'R!<W#XX58BH/XG&*P_\`A7NKG/\`
MIED/^^_\*='\.M2W`R:A:H/58V8_KBGIV_'_`(`6AW,>[N[K4[V:Z>,F]O6"
M10QG('91^`ZFO4-*LAIVE6MD&W>1$J%O4@<G\ZS="\)V>C/]H+M<W9&/.D`&
MWU"CM_.MT=*DC2^AYUXOLFLM>EF88M]14$-V$@7!!_#G\ZBMO$%C+HJ:)K\%
MRT,!&R>W/)`Z9[\=.*]!U#3K75+1K6\A66%^JGL>Q!['WKCKKX=RB5C9ZG^[
MS\JW$>Y@/]X'G\J$[,<5'J9FWP*<?/JIS_UTH*^!1QNU3_Q^K:_#S4A_R_V@
M_P"V;4?\*[U+_H(6O_?MJJ_E^/\`P"_=[E7'@@#C^U_P#UL^%?\`A&_[8/\`
M9(OQ<^2<_:`VW;D9Z_A5-/`.JQ_=O[//KY;_`.-:WA_PO?Z3JOVRZNX)E$)C
M`C1@>2#W/M1?^K_\`B7D=0[!$+'H!DUS(^(.B$9"WA';_1FYKI95+QNHZD$5
MPD?@35XXEB&I6>U?^F3?XU*V$:W_``L'1,X*WF?>W-9VL^/8YK22WTNWF#R*
M5\^9=H3/<#J34+?#[4G^]J-J?^V3?XU);_#F0R#[5J@"=Q##@GZ$DX_*G\OQ
M_P"`7[G<XM3L<*DFQTP5(/S*1T-=W8?$.W$"IJ5G<),!AGA4.C'UZY'TK8D\
M(:-)I:Z?]DV1H=RR*?W@;NV[N?KQ7/S?#F?S"8-40KGCS8#G'N0?Z"I6FF_]
M?,IRC+<U!\0-%/1+P_2W/%/C\=Z3)+'&(KT&1PB[K<@9)Q6,GP^U&/&W5+<?
M]L#_`(U/'X&O_.A>74H&6.19"!"03@Y]:K2^WX_\`S=NAVU+24M(04444`%%
M%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4AI:0TF!Y*O,\?I]O\`
M3_II7K5<E_P@<?V@2G5;@JLWFA#&N,[MV*ZT=.:I_JQ)6%HHHI#"BBB@`HHH
MH`*Y#QX1G2SG&)F[?[-=?6/K^@)KB0*UU+;&!BP:,`DY&.]'=>HFKJQC_#_[
MFJ<$?Z0O_H(KI=3OO[.L'NO*:8J54(I`+%F"CD^YJEX?T!-`CG1+F6X\]P[-
M(H!!`QVJUK.GG5-,DLPRCS&0G=G&`X)''L*K2^I4;75R.RU8W+W<,]J]M<6@
M#21E@P(()!!'T-$&M07']G;%.;]2RC<"4^3=S_*IH-,M;.VFALX4A\W.XCDL
M<8R3U-9UCX:AL7TJ6&*VCELT*S/''@R93;U^O/-/W2O=U+EYK$-GJMII[QNS
M76?W@^['_=W?4@@?2C4-2FM;N"UMK)KJ69&?`D5``N`>O^\*I:CX<EOY[N[^
MV21W#%#;!7(1-G*;AW^;)_&K&IZ%#JU[!+>(DD,<,D90YSEMO(/X&CW=!^[H
M)+X@A3PV=;CMY9(PN?)&-Y.[:1Z9S2R^(;5+K3+>-'E_M(91EQA%VY!;Z]*!
MI4Y\.PZ8\D7FQ"-=ZKA2%8'I[@?G5.U\,RVUVDWVE76*\\R)2/N0A7P@^C.?
MPH]T:4-31U#6(=.O;.UDC=S=/MW+TC'`!;V)('XT[4=3-G-!;06S7-U<;C'$
MK!>%^\Q)Z`9'YBJ.J>'6U6XNIY+N2-GB6.W$;E0NWY@6'?YN?P%6;ZPO9+BR
MO[9X?M=LC(ZR9".K`;AD<CE011:.@K1T%FUCR=%;46LYE=6"&!\*P;<%QGIC
M)Z],5-;7MQ);2S75G]G\L$A1*K[@!GMTJI>Z9>WWAZ2RN)X9KJ1@S%E(CX<-
MMP.<8&/6I]/LI8;.6VFM[2W1\[5M2<<CDG('-+2PO=L+#JL<PT\B-Q]OC+ID
MCY0%W<_G40U:[.L_V=_9C8"[_.\Y<;,XW8Z_A4.G:5?PS6(NY+?RM/B,<1BW
M;I,@*"<].!TYYJ_]B?\`MHWV]=AMA#M[YW9S1H#Y4.BO5EU*>R",&@C20L>A
M#%@/_035*WUUKFX0QV$YLI93$ET"""P)&2O4+D$9JU#9/%K%U>EU*3PQ1A>X
M*ER?_0A5*QTW4[$Q6<5S`MA#*SA@"960DD(1T')Z^@HT#W2S>:S#9:I9V#QN
MS71(WK]V/^[N^IX%3R7JQZC!9%&+31NX;L-N/_BJR]2\.2:A/=W1O)(YWV?9
M@KD(FSYEW#O\V35K4+._?4+2]L_LQ>&-T=)F8`[MO((!_NT[(+1T'ZKJPTUK
M:)8#-/=.4B3>$&0"3ECP.!^-6K.X>YMEEDMY+=SD-')C*D'';@CWJEJEC=7]
MI"ABLYL<S6]PNZ-^.QQD$'H<4_0].DTO31;2R!SO9@JDE8P3D(N><#IS2TL#
MMR^9HT4E+4D!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!
M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%
M%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`444
M4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110
M`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!
21110`4444`%%%%`!1110!__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
